Eurofins relocates to expand API capabilities in Canada

By Ben Hargreaves

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Eurofins API Active pharmaceutical ingredients Manufacturing facility

Eurofins announces that it relocated and expanded its API development laboratories by moving to a new space in Ontario, Canada.

Eurofins CDMO Alphora, the Canadian division of Eurofins, moved into its new active pharmaceutical ingredients (APIs) labs within the Sheridan Research Park location.

The building covers 56,000-square-feet and will provide the base for Eurofins’ API process R&D activity, solid-state R&D, and its analytical services team.

Contained within the new facility are 26 fume hoods supporting process R&D, a 50L scale kilo laboratory equipped with six walk-in fume hoods, current good manufacturing practice (cGMP) analytical services, and highly potential active pharmaceutical ingredients (HPAPI) development laboratories. The new location also contains offices and space for client meetings.

According to Eurofins, the location expands the company’s capacity for the growth of client programs, and offers new kilo laboratory services for larger quantities of preclinical materials for toxicological studies.

With the new site, Eurofins has a 14-acre campus located over two ‘nearly’ adjacent within the Sheridan Research Park. The new API development labs are located opposite the corporate site at the second location, which also houses drug product development and manufacturing.

The second site also contains a newly complete 100L scale GMP HPAPI facility, and has a 2,000L GMP API plant that will be operational by mid-2023. Eurofins also states that the new location is 2.5km away from the company’s existing API production facility.

Expanding global capabilities

The most recent expansion to its Canadian capacity arrives after a number of acquisitions in 2022 drove an expansion in capabilities across various countries.

In June 2022, the company acquired a majority stake in Ajal for Laboratories, providing Eurofins with 3,000-square-meters of laboratory space, based in Riyadh, Saudi Arabia. The deal represented Eurofins’ first acquisition in the country.

Prior to that, Eurofins had added Repertoire Genesis to its business, which expanded its clinical and biopharma service offering in Japan. The company provides TCR/BCR repertoire profiling, allowing researchers to determine the specific pathophysiological status of immune responses derived from cancer, autoimmune diseases, transplants, and infectious diseases.

In February 2022, the company also purchased Genetic Testing Service JSC, a Vietnamese genetic testing company.

Explaining its decision at the time, Eurofins stated that specialized genetic testing to support the detecting of cancer, chromosomal disorders, and the prevention of genetic disorders represents a “significant growth opportunity.”

The company also outlined that making an acquisition in Vietnam fit into a wider strategy to expand its presence in South East Asia.

Related news

Related product

A Guide Through the API Drug Development Pipeline.

A Guide Through the API Drug Development Pipeline.

Content provided by Lonza Small Molecules | 04-Apr-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more